alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.4

April 9, 2009

Kevin G. Wills

1310 Legacy Drive

Birmingham, AL 35242



|Re: | Employment Agreement between Saks Incorporated and Kevin G. Wills, dated as of April 17, 2007, as amended on December 18, 2008 (Employment Agreement)
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Kevin:

This letter agreement serves to
amend the Employment Agreement in accordance with Section 13(c) thereof. All capitalized terms in this letter agreement shall have the same meaning as in the Employment Agreement, except as provided herein.

Effective June 1, 2009, solely for purposes of Sections 3(a) and 3(b), Executives Base Salary shall be reduced 5% from $615,000.00 to $584,250.00.
Notwithstanding the preceding sentence, for all other purposes of the Agreement, the term Base Salary shall be $615,000.00 (or any higher rate from time to time in effect).



---

The changes to the Employment Agreement described above are subject to the approval of the Human Resources and
Compensation Committee of the Companys Board of Directors and shall only become effective upon such approval.



|                                         
|-----------------------------------------
|Sincerely,                               
|                                         
|SAKS INCORPORATED                        
|                                         
|/s/ Christine A. Morena                  
|Christine A. Morena                      
|Executive Vice President, Human Resources



|                                                                                                                                                                         |  |                   
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |  | ------------------
|By signing on the line below, Executive expressly agrees to the change in Base Salary and waives Executives right to claim Good Reason under the Employment Agreement
|                                                                                                                                                                         | 
|By:                                                                                                                                                                      |  | /s/ Kevin G. Wills
|                                                                                                                                                                         |  | Kevin G. Wills    
|                                                                                                                                                                         | 
|Title:                                                                                                                                                                   |  | EVP and CFO       

Date: 4/17/09



Page 2
IV 

115TH CONGRESS 

1ST SESSION H. RES. 148 

Expressing support for the designation of ‘‘National Multiple Myeloma 

Awareness Month’’. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 17, 2017 

Mr. HIGGINS of New York submitted the following resolution; which was 

referred to the Committee on Oversight and Government Reform 

RESOLUTION 

Expressing support for the designation of ‘‘National Multiple 

Myeloma Awareness Month’’. 

Whereas multiple myeloma (or myeloma) is a cancer of plasma cells in the bone marrow and is called ‘‘multiple’’ because the cancer can occur at various sites in the body; 

Whereas multiple myeloma causes a variety of adverse health 

effects, including a weakened immune system, anemia, 

kidney damage, and bone deterioration; 

Whereas multiple myeloma is the second most common blood 

cancer worldwide; 

Whereas multiple myeloma currently affects more than 

100,000 people in the United States, with about 30,330 

new diagnoses and 12,650 deaths from the disease occurring in 2016, according to the Surveillance, Epidemimstockstill on DSK3G9T082PROD with BILLS

2 

•HRES 148 IH 

ology, and End Results Program of the National Cancer 

Institute; 

Whereas although multiple myeloma has been and continues 

to be most frequently diagnosed among those 65 and 

over, the disease is increasingly being diagnosed in 

younger individuals, including those in their 30s, 40s and 

50s; 

Whereas multiple myeloma is almost twice as likely to occur 

among African-Americans and is one of the leading 

causes of cancer deaths among African-Americans, with 

scientific understanding of the disparity remaining unknown; 

Whereas although the cause of multiple myeloma remains unknown, robust research is being performed in the United 

States and internationally into potential genetic, environmental, and other risk factors; 

Whereas additional new drugs and therapies are in the research phase, with patient enrollment in clinical trials 

playing an important role in determining safe and effective treatments; 

Whereas understanding and treatment of multiple myeloma 

has been greatly furthered by advocacy initiatives promoting awareness, education, research, peer review, and 

collaboration and such efforts are to be highly commended; 

Whereas greater awareness of multiple myeloma among clinicians and the public can lead to earlier detection and 

treatment, improving health outcomes and bringing comfort to patients and their families; and 

mstockstill on DSK3G9T082PROD with BILLS

3 

•HRES 148 IH 

Whereas March would be an appropriate month to designate 

as ‘‘National Multiple Myeloma Awareness Month’’: Now, 

therefore, be it 

1 Resolved, That the House of Representatives supports 

2 the designation of ‘‘National Multiple Myeloma Awareness 

3 Month’’ to increase public knowledge of the disease and 

4 advance the vision of finding a cure for multiple myeloma. 

Æ 

mstockstill on DSK3G9T082PROD with BILLS
# L_2022135DE.01003401.xml

| 12.5.2022 | DE | Amtsblatt der Europäischen Union | L 135/34 |
| --- | --- | --- | --- |

12.5.2022

DE

Amtsblatt der Europäischen Union

L 135/34

---

Berichtigung der Delegierten Verordnung (EU) 2018/625 der Kommission vom 5. März 2018 zur Ergänzung der Verordnung (EU) 2017/1001 des Europäischen Parlaments und des Rates über die Unionsmarke und zur Aufhebung der Delegierten Verordnung (EU) 2017/1430

(
  Amtsblatt der Europäischen Union L 104 vom 24. April 2018
  )

Seite 7, Artikel 7 Absatz 2 Buchstabe f:

Anstatt:

| „f) | wird der Widerspruch auf eine Marke gestützt, die eine im Sinne des Artikels 8 Absatz 5 der Verordnung (EU) 2017/1001 bekannte Marke ist, ist dies für die Union oder den betreffenden Mitgliedstaat für die gemäß Artikel 2 Absatz 2 Buchstabe g angegebenen Waren oder Dienstleistungen zusätzlich zu dem in Buchstabe a aufgeführten Nachweis zu belegen; ferner sind Beweismittel und Bemerkungen dazu einzureichen, dass die Benutzung der angemeldeten Marke die Unterscheidungskraft oder die Wertschätzung der älteren Marke ohne rechtfertigenden Grund in unlauterer Weise ausnutzen oder beeinträchtigen würde.“ |
| --- | --- |

„f)

wird der Widerspruch auf eine Marke gestützt, die eine im Sinne des Artikels 8 Absatz 5 der Verordnung (EU) 2017/1001 bekannte Marke ist, ist dies für die Union oder den betreffenden Mitgliedstaat für die gemäß Artikel 2 Absatz 2 Buchstabe g angegebenen Waren oder Dienstleistungen zusätzlich zu dem in Buchstabe a aufgeführten Nachweis zu belegen; ferner sind Beweismittel und Bemerkungen dazu einzureichen, dass die Benutzung der angemeldeten Marke die Unterscheidungskraft oder die Wertschätzung der älteren Marke ohne rechtfertigenden Grund in unlauterer Weise ausnutzen oder beeinträchtigen würde.“

muss es heißen:

| „f) | wird der Widerspruch auf eine Marke gestützt, die eine im Sinne des Artikels 8 Absatz 5 der Verordnung (EU) 2017/1001 bekannte Marke ist, ist dies für die Union oder den betreffenden Mitgliedstaat für die gemäß Artikel 2 Absatz 2 Buchstabe g angegebenen Waren oder Dienstleistungen zusätzlich zu dem in Buchstabe a aufgeführten Nachweis zu belegen; ferner sind Beweismittel oder Bemerkungen dazu einzureichen, dass die Benutzung der angemeldeten Marke die Unterscheidungskraft oder die Wertschätzung der älteren Marke ohne rechtfertigenden Grund in unlauterer Weise ausnutzen oder beeinträchtigen würde.“ |
| --- | --- |

„f)

wird der Widerspruch auf eine Marke gestützt, die eine im Sinne des Artikels 8 Absatz 5 der Verordnung (EU) 2017/1001 bekannte Marke ist, ist dies für die Union oder den betreffenden Mitgliedstaat für die gemäß Artikel 2 Absatz 2 Buchstabe g angegebenen Waren oder Dienstleistungen zusätzlich zu dem in Buchstabe a aufgeführten Nachweis zu belegen; ferner sind Beweismittel oder Bemerkungen dazu einzureichen, dass die Benutzung der angemeldeten Marke die Unterscheidungskraft oder die Wertschätzung der älteren Marke ohne rechtfertigenden Grund in unlauterer Weise ausnutzen oder beeinträchtigen würde.“

---
* Pursuant to 5 TH C IR . R. 47.5, the court has determined that

this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals

Fifth Circuit 

## FILED October 25, 2004 Charles R. Fulbruge III Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 03-51117 Summary Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus ARMANDO MARTINEZ, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Western District of Texas USDC No. DR-03-CR-29-1-AML

-------------------- Before GARZA, DeMOSS, and CLEMENT, Circuit Judges.

PER CURIAM: *Armando Martinez appeals his sentence following a guiltyplea conviction for distribution of cocaine. Martinez argues that the district court erred in finding that he possessed a firearm during the commission of the offense and, as a result, in imposing a two-level enhancement pursuant to U.S.S.G. § 2D1.1(b)(1) and denying a safety-valve adjustment pursuant to U.S.S.G. § 5C1.2.No. 03-51117 -2- Section 2D1.1(b)(1) calls for a two-level increase in the offense level for a drug trafficking offense “[i]f a dangerous weapon (including a firearm) was possessed.” U.S.S.G. § 2D1.1(b)(1). Because the confidential informant saw, on at least one occasion, Martinez wearing a weapon during the offense and a weapon was found in the same location where a number of offenses occurred, we find that the district court did not clearly err in finding that Martinez possessed a firearm during the commission of the offense. See United States v. Jacquinot , 258 F.3d 423, 430 (5th Cir. 2001). Additionally, the district court’s finding that Martinez possessed a firearm for purposes of U.S.S.G. § 2D1.1(b)(1) also “disqualified [him] from being eligible for the ‘safety valve’ provision of U.S.S.G. § 5C1.2.” United States v. Flucas , 99 F.3d 177, 178-79 (5th Cir. 1996). Because Martinez has failed to show that the district court erred in imposing the U.S.S.G. § 2D1.1(b)(1) enhancement, he consequently has also failed to show that the district court erred in determining that he was ineligible under U.S.S.G. § 5C1.2. See id. ; Vasquez , 161 F.3d 909, 912-13 (5th Cir. 1998). Accordingly, the district court’s judgment is AFFIRMED.
**Exhibit 32**

 

**CERTIFICATIONPURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with theQuarterly Report of Pace Medical, Inc. (the “Company”) on Form 10-QSB for theperiod ended September 30, 2003 as filed with the Securities and ExchangeCommission on the date hereof (the “Report”), I, Ralph Hanson, President andTreasurer of the Company, being the chief executive officer and the chieffinancial officer of the Company, certify, pursuant to 18 U.S.C. § 1350, asadopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Reportfully complies with the requirements of section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

 

(2) Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 

 
| /s/ Ralph  Hanson         |   |
|---------------------------|--------|
|                      |
| Ralph Hanson              |
| President  and  Treasurer |
| November 14,  2003        |

 

----
#### Ætna Life Insurance Company *v.*Sellers et al.

[No. 19,179.

Filed March 27, 1900.]

Appeal and *Error.*— Correction *of Record.*— An appeal from a proceeding to correct the record of a case pending on appeal will not be considered unless the transcript of such proceeding is filed as a part of the original appeal.

From the Wells Circuit Court.

*Appeal dismissed.*

*H. C. Pettit, P. C. Dailey, A. Simmons*áud *J. S. Dailey,*for appellant.

*Mo.clc & Sons, G. T. Williamson, A. N. Martini and. W. H. Eichhorn,*for appellees.

Baker, J.

While the appeal of *Aetna Life Ins. Co.*v. *Sellers, ante,*370, decided at this term, was pending, the appellee began proceedings in the trial court to correct the record of the original case by supplying an exhibit .to his cross-complaint and by correcting the bill of exceptions containing the evidence. The trial court corrected the record, and the corrections were brought to this court on appellee’s application by *certiorari,*as a part of the pending appeal. In this apr peal, the transcript contains the proceedings had on appellee’s application to the trial court to correct its record. As those proceedings were auxiliary to the original cause, this transcript should have been filed as a part of the original appeal, if appellant desired to question the trial court’s rulings in making the corrections. *Hamilton*v. *Burch,*28 Ind. 233 ; *Seig*v. *Long,*72 Ind. 18; *Hannah*v. *Dorrell,*73 Ind. 465; *Tomlinson*v. *Harris,*130 Ind. 339; *Driver*v. *Driver,*153 Ind. 88; Ewbank’s Manual, §214.

Appeal dismissed.
# L_2018061EN.01000501.xml

| 3.3.2018 | EN | Official Journal of the European Union | L 61/5 |
| --- | --- | --- | --- |

3.3.2018

EN

Official Journal of the European Union

L 61/5

---

Corrigendum to Commission Implementing Regulation (EU) 2018/303 of 27 February 2018 concerning the non-approval of the active substance Reynoutria sachalinensis extract, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market

(
  Official Journal of the European Union L 59 of 1 March 2018
  )

The publication of Commission Implementing Regulation (EU) 2018/303 is to be considered null and void.

---
<PAGE>   1
                                                               Exhibit 5.1  
                 


             [GRAHAM & JAMES LLP/RIDDELL WILLIAMS P.S. LETTERHEAD]



August 8, 1997

Innova Corporation
Gateway North, Building 2
3325 South 116th Street
Seattle, WA 98168-1974

RE:  3,162,500 SHARES OF COMMON STOCK OF INNOVA CORPORATION

Ladies and Gentlemen:

This opinion is furnished in connection with a Registration Statement on Form
S-1 (Registration No. 333-29547), as amended (the "Registration Statement"), of
Innova Corporation, a Washington corporation (the "Company"), under which
2,750,000 shares of Common Stock of the Company (the "Common Stock"), together
with up to an additional 412,500 shares of Common Stock to cover
over-allotments, are being registered by the Company for sale under the
Securities Act of 1933, as amended (all of such shares will be referred to as
the "Shares").

As counsel for the Company, we are familiar with the Company's Restated Articles
of Incorporation, as amended, the Company's Amended and Restated Bylaws, as
amended, and the records of the corporate proceedings of the Company, and we
have assisted in the preparation of the Registration Statement, including the
Prospectus contained therein.

Based on the foregoing, we are of the opinion that, when (a) the Registration
Statement shall have been declared effective by order of the Securities and
Exchange Commission, (b) the Shares shall have been offered and sold in the
manner referred to in the Registration Statement, (c) certificates for the
Shares shall have been duly issued by the Company and registered by its
registrar, and (d) the Company shall have received the consideration required
for the Shares as contemplated by the Registration Statement, the Shares will be
validly issued, fully paid and nonassessable.


<PAGE>   2
Innova Corporation
August 8, 1997
Page 2


We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and to the inclusion in the Prospectus contained therein
of the reference to our firm under the heading "Legal Matters." In giving such
consent, we do not admit that we are in the category of the persons whose
consent is required under Section 7 of the Securities Act of 1933, as amended.

Very truly yours,


/s/ BENJAMIN F. STEPHENS
Benjamin F. Stephens
       of
Graham & James LLP/Riddell Williams P.S.


BFS:ml
.£

Or

Of ~i*A?, 7?

Ml, THIS £Qt/A

iT

(N

7~O

3m

& T

!■
TO 7~t>

s,

Am AttfcA/fiT'/Jl O/%.

Oaj

To

THB

7- A± /T /y'/is Been/

}Bn.tePjTAS

r/9/fr

4/*/>*'//avTj //
79/97-

AMARILLO TX

O4 AUG 2OXS PM

O*

32-OO

PB2CSS3O3
I 

118TH CONGRESS 

2D SESSION H. R. 7216 

To direct the Secretary of Health and Human Services to revise regulations 

to remove the requirement under the Medicare program that an ambulatory surgical center shall report the COVID–19 vaccination status of 

health care personnel. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 1, 2024 

Ms. VAN DUYNE (for herself, Mr. SMITH of Nebraska, Ms. TENNEY, Mrs. 

MILLER-MEEKS, Mr. POSEY, Mr. BACON, Mr. BEAN of Florida, Mr. 

YAKYM, Mr. SELF, Mr. JACKSON of Texas, Mr. MCCORMICK, Mr. CLOUD, 

Mr. TIFFANY, Ms. HAGEMAN, Mr. GOSAR, Mr. HARRIS, Mr. NEHLS, Mr. 

BIGGS, Mr. DAVIDSON, and Mr. WESTERMAN) introduced the following 

bill; which was referred to the Committee on Energy and Commerce, and 

in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of 

such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To direct the Secretary of Health and Human Services to 

revise regulations to remove the requirement under the 

Medicare program that an ambulatory surgical center 

shall report the COVID–19 vaccination status of health 

care personnel. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7216 IH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Protecting Healthcare 

3 Employee Privacy Act’’. 

4 SEC. 2. REMOVING COVID–19 VACCINATION STATUS RE5 PORTING REQUIREMENT FOR AMBULATORY 

6 SURGICAL CENTERS. 

7 Not later than 45 days after the date of the enact8 ment of this Act, the Secretary of Health and Human 

9 Services shall revise sections 416.300 through 416.330 of 

10 title 42, Code of Federal Regulations (or any successor 

11 regulations) to remove the requirement under the Medi12 care program that an ambulatory surgical center shall re13 port the COVID–19 vaccination status of health care per14 sonnel. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
# L_2019215DE.01000301.xml

| 19.8.2019 | DE | Amtsblatt der Europäischen Union | L 215/3 |
| --- | --- | --- | --- |

19.8.2019

DE

Amtsblatt der Europäischen Union

L 215/3

---

Berichtigung der Verordnung (EU) 2018/1727 des Europäischen Parlaments und des Rates betreffend die Agentur der Europäischen Union für justizielle Zusammenarbeit in Strafsachen (Eurojust) und zur Ersetzung und Aufhebung des Beschlusses 2002/187/JI des Rates

(
  Amtsblatt der Europäischen Union L 295 vom 21. November 2018
  )

Seite 152, Artikel 12, Titel

Anstatt:

„Entschädigungsmechanismus für die Wahl zum Präsidenten oder Vizepräsidenten“

muss es heißen:

„Entschädigungsmechanismus für die Wahl zum Präsidenten“.

---
# L_2019336DE.01031401.xml

| 30.12.2019 | DE | Amtsblatt der Europäischen Union | L 336/314 |
| --- | --- | --- | --- |

30.12.2019

DE

Amtsblatt der Europäischen Union

L 336/314

---

Berichtigung des Durchführungsbeschlusses (EU) 2019/1739 der Kommission vom 16. Oktober 2019 über Dringlichkeitsmaßnahmen zum Schutz der Union gegen die Einschleppung und Ausbreitung des Rose-rosette-Virus

(Amtsblatt der Europäischen Union L 265 vom 18. Oktober 2019)

Seite 12, Erwägungsgrund 7 Satz 1:

Anstatt:

Anstatt:

„Es sollten Anforderungen an das Verbringen von Pflanzen, ausgenommen Samen, der Sorte Rosa spp. mit Ursprung in Kanada, Indien oder den USA (spezifizierte Pflanzen) in die Union festgelegt und amtliche Kontrollen bei ihrer Verbringung in die Union durchgeführt werden.“

muss es heißen:

muss es heißen:

„Es sollten Anforderungen an das Verbringen von Pflanzen, ausgenommen Samen, von Rosa spp. mit Ursprung in Kanada, Indien oder den USA (spezifizierte Pflanzen) in die Union festgelegt und amtliche Kontrollen bei ihrer Verbringung in die Union durchgeführt werden.“

Seite 13, Artikel 1 Buchstabe b:

Anstatt:

Anstatt:

| „b) | ‚spezifizierte Pflanzen‘ Pflanzen, ausgenommen Samen, der Sorte Rosa spp. mit Ursprung in Kanada, Indien oder den USA;“ |
| --- | --- |

„b)

‚spezifizierte Pflanzen‘ Pflanzen, ausgenommen Samen, der Sorte Rosa spp. mit Ursprung in Kanada, Indien oder den USA;“

Rosa

muss es heißen:

muss es heißen:

| „b) | ‚spezifizierte Pflanzen‘ Pflanzen, ausgenommen Samen, von Rosa spp. mit Ursprung in Kanada, Indien oder den USA;“ |
| --- | --- |

„b)

‚spezifizierte Pflanzen‘ Pflanzen, ausgenommen Samen, von Rosa spp. mit Ursprung in Kanada, Indien oder den USA;“

Rosa

---